DexCom stock down 17% after hours as Q2 results miss expectations
Dragoljub Bankovic


DexCom (NASDAQ:DXCM) stock fell 17% after hours Thursday, as the diabetes medical device maker reported Q2 earnings that missed estimates.
DXCM posted Q2 non-GAAP EPS of $0.17 which missed expectations by $0.02. Its Q2 revenue of $696.2M also missed by $13.13M.
The company also tightened its FY 2022 revenue guidance range. It now expects FY 2022 revenue of about $2.86B to $2.91B, from a previous forecasted range of $2.82B to $2.94B. The consensus revenue estimate for FY is $2.93B.
The company reiterated its previous guidance for FY 2022 non-GAAP gross profit margin, non-GAAP operating margin and adj. EBITDA margin.
DexCom's (DXCM) net income narrowed from a year ago, as quarterly total operating expenses rose 17.8% Y/Y to $372.5M.
However, Q2 revenue grew 17% Y/Y, helped by volume growth in conjunction with "strong new customer additions," DXCM said in the earnings report.
DexCom (DXCM) stock has lost 35.2% YTD.